Trial Profile
An open label,prospective study evaluated the safety and efficacy of Deferasirox in patients with hereditary hemochromatosis and iron overload
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemochromatosis; Iron overload
- Focus Adverse reactions; Therapeutic Use
- 27 Nov 2016 New trial record